(Hypertension. 2000;36:1072.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
Relation Between Serum Uric Acid and Risk of Cardiovascular Disease in Essential Hypertension
The PIUMA Study
From Ospedale Raffaello Silvestrini, Unità Operativa di Malattie Cardiovascolari, Perugia (P.V., C.P.); Ospedale Beato G. Villa, Città della Pieve (G.S.); and Dipartimento di Medicina Interna, Università di Perugia (G.R., F.S., P.B.), Italy.
Correspondence to Dr Paolo Verdecchia, Ospedale "R. Silvestrini," Dipartimento di Discipline Cardiovascolari, S. Andrea delle Fratte, 06156 Perugia PG, Italy. E-mail verdec{at}tin.it
Abstract—The question of serum uric acid as an independent risk factor in subjects with essential hypertension remains controversial. For up to 12 years (mean, 4.0) we followed 1720 subjects with essential hypertension. At entry, all subjects were untreated and all were carefully screened for absence of cardiovascular disease, renal disease, cancer, and other important disease. Outcome measures included total cardiovascular events, fatal cardiovascular events, and all-cause mortality. During 6841 person-years of follow-up there were 184 cardiovascular events (42 fatal) and 80 deaths from all causes. In the 4 quartiles of serum uric acid (division points: 0.268, 0.309, and 0.369 mmol/L [4.5, 5.2, and 6.2 mg/dL] in men; 0.190, 0.232, and 0.274 mmol/L [3.2, 3.9, and 4.6 mg/dL] in women), the rate (per 100 person-years) of cardiovascular events was 2.51, 1.48, 2.66, and 4.27, that of fatal cardiovascular events was 0.41, 0.33, 0.38, and 1.23, and that of all-cause deaths was 1.01, 0.55, 0.93, and 2.01, respectively. The relation between uric acid and event rate was J-shaped in both genders. After adjustment for age, gender, diabetes, total cholesterol/HDL cholesterol ratio, serum creatinine, left ventricular hypertrophy, ambulatory blood pressure, and use of diuretics during follow-up, uric acid levels in the highest quartile were associated with increased risk for cardiovascular events (relative risk, 1.73; 95% CI, 1.01 to 3.00), fatal cardiovascular events (relative risk, 1.96; 95% CI, 1.02 to 3.79), and all-cause mortality (relative risk, 1.63; 95% CI, 1.02 to 2.57) in relation to the second quartile. In untreated subjects with essential hypertension, raised uric acid is a powerful risk marker for subsequent cardiovascular disease and all-cause mortality.
Key Words: uric acid • blood pressure • cardiovascular disease • hypertension, essential • blood pressure monitoring • hypertrophy, left ventricular
This article has been cited by other articles:
 |
|
 |
|
  C. Meisinger, W. Koenig, J. Baumert, and A. Doring Uric Acid Levels Are Associated With All-Cause and Cardiovascular Disease Mortality Independent of Systemic Inflammation in Men From the General Population: The MONICA/KORA Cohort Study Arterioscler. Thromb. Vasc. Biol., June 1, 2008; 28(6): 1186 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Strasak, E. Ruttmann, L. Brant, C. Kelleher, J. Klenk, H. Concin, G. Diem, K. Pfeiffer, H. Ulmer, and and the VHM&PP Study Group Serum Uric Acid and Risk of Cardiovascular Mortality: A Prospective Long-Term Study of 83 683 Austrian Men Clin. Chem., February 1, 2008; 54(2): 273 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Baker, H. R. Schumacher, and E. Krishnan Serum Uric Acid Level and Risk for Peripheral Arterial Disease: Analysis of Data From the Multiple Risk Factor Intervention Trial Angiology, September 1, 2007; 58(4): 450 - 457. [Abstract] [PDF]
|
|
|
|
|
|
T. Fukai Extracellular SOD Inactivation in High-Volume Hypertension: Role of Hydrogen Peroxide Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 442 - 444. [Full Text] [PDF]
|
|
|
|
 |
|
 V. G. Athyros, D. P. Mikhailidis, E. N. Liberopoulos, A. I. Kakafika, A. Karagiannis, A. A. Papageorgiou, K. Tziomalos, E. S. Ganotakis, and M. Elisaf Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study Nephrol. Dial. Transplant., January 1, 2007; 22(1): 118 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. George, E. Carr, J. Davies, J.J.F. Belch, and A. Struthers High-Dose Allopurinol Improves Endothelial Function by Profoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric Acid Circulation, December 5, 2006; 114(23): 2508 - 2516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C.P. Franco, D. M.J. Christofalo, A. L. Sawaya, S. A. Ajzen, and R. Sesso Effects of Low Birth Weight in 8- to 13-Year-Old Children: Implications in Endothelial Function and Uric Acid Levels Hypertension, July 1, 2006; 48(1): 45 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Lee, Y.-G. Kim, Y.-H. Choi, W. Huh, D. J. Kim, and H. Y. Oh Serum Uric Acid Is Associated With Microalbuminuria in Prehypertension Hypertension, May 1, 2006; 47(5): 962 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Iwashima, T. Horio, K. Kamide, H. Rakugi, T. Ogihara, and Y. Kawano Uric Acid, Left Ventricular Mass Index, and Risk of Cardiovascular Disease in Essential Hypertension Hypertension, February 1, 2006; 47(2): 195 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Viazzi, D. Parodi, G. Leoncini, A. Parodi, V. Falqui, E. Ratto, S. Vettoretti, G. P. Bezante, M. Del Sette, G. Deferrari, et al. Serum Uric Acid and Target Organ Damage in Primary Hypertension Hypertension, May 1, 2005; 45(5): 991 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sundstrom, L. Sullivan, R. B. D'Agostino, D. Levy, W. B. Kannel, and R. S. Vasan Relations of Serum Uric Acid to Longitudinal Blood Pressure Tracking and Hypertension Incidence Hypertension, January 1, 2005; 45(1): 28 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-P. Hsu, M.-F. Pai, Y.-S. Peng, C.-K. Chiang, T.-I Ho, and K.-Y. Hung Serum uric acid levels show a 'J-shaped' association with all-cause mortality in haemodialysis patients Nephrol. Dial. Transplant., February 1, 2004; 19(2): 457 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A J. A. Khaja, R. P Sequeira, and A. H. Damanhori Treatment of Hypertension in Bahrain Ann. Pharmacother., October 1, 2003; 37(10): 1511 - 1517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. T. Rott and C. A. Agudelo Gout JAMA, June 4, 2003; 289(21): 2857 - 2860. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Johnson, D.-H. Kang, D. Feig, S. Kivlighn, J. Kanellis, S. Watanabe, K. R. Tuttle, B. Rodriguez-Iturbe, J. Herrera-Acosta, and M. Mazzali Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease? Hypertension, June 1, 2003; 41(6): 1183 - 1190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kanellis, S. Watanabe, J. H. Li, D. H. Kang, P. Li, T. Nakagawa, A. Wamsley, D. Sheikh-Hamad, H. Y. Lan, L. Feng, et al. Uric Acid Stimulates Monocyte Chemoattractant Protein-1 Production in Vascular Smooth Muscle Cells Via Mitogen-Activated Protein Kinase and Cyclooxygenase-2 Hypertension, June 1, 2003; 41(6): 1287 - 1293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. de Leeuw, L. Thijs, W. H. Birkenhager, S. M. Voyaki, A. D. Efstratopoulos, R. H. Fagard, G. Leonetti, C. Nachev, J. C. Petrie, J. L. Rodicio, et al. Prognostic Significance of Renal Function in Elderly Patients with Isolated Systolic Hypertension: Results from the Syst-Eur Trial J. Am. Soc. Nephrol., September 1, 2002; 13(9): 2213 - 2222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Watanabe, D.-H. Kang, L. Feng, T. Nakagawa, J. Kanellis, H. Lan, M. Mazzali, and R. J. Johnson Uric Acid, Hominoid Evolution, and the Pathogenesis of Salt-Sensitivity Hypertension, September 1, 2002; 40(3): 355 - 360. [Abstract] [Full Text] [PDF]
|
|